Ozempic or Wegovy Out of Stock in India? Here Are Your Options
A missed GLP-1 dose isn't a minor inconvenience, it stalls your progress and can worsen side effects when you restart. If your pharmacy is out of stock, here is what actually works in 2026.
ALTRcare Medical Team
Clinical Editorial
If you've been turned away from a pharmacy counter or watched your usual brand vanish for weeks, you already know the real problem with GLP-1 stockouts: the treatment only works if you take it consistently. A gap doesn't just pause your progress, restarting at the wrong dose can bring back the early side effects you'd already moved past.
Updated 8 October 2026
Semaglutide supply in India is no longer the problem it was in 2025. Generic semaglutide is made domestically by more than a dozen companies, and Novo Nordisk's own prices fell in April 2026 (Ozempic and Wegovy from ₹5,660 a month). The more common risk now is the opposite: cheap pens from unlicensed sellers. In April 2026, Haryana regulators seized more than 260 counterfeit Mounjaro pens that were being sold online, so if your usual pharmacy is out, switch brands through your doctor rather than buying from a marketplace.
Why Ozempic and Wegovy go out of stock
Global demand for semaglutide has outpaced manufacturing for years. India, as a smaller and lower-priced market, has historically sat behind larger markets in the supply queue. Add the early reliance on imported pens through informal channels, and a delay anywhere in the chain became a missed dose here.
Why gaps matter clinically
GLP-1s are titrated up slowly so your body adapts. If you stop for a while and then jump back in at your previous dose, nausea and GI effects can return. Supply continuity isn't a luxury; it's part of the treatment working.
The 2026 fix: the molecule is no longer scarce
Here's what changed. After the semaglutide patent expired on 20 March 2026, Indian manufacturers began producing the same molecule as Ozempic and Wegovy; by May 2026 there were 35 brands from 17 companies. Supply is now spread across many domestic producers rather than concentrated in one imported brand, which makes a single stockout far less likely to leave you without options. By June 2026, generics already made up 82% of semaglutide units sold in India.
- Generic semaglutide: the identical molecule, DCGI-approved, from ₹1,800/month in a pen, made domestically.
- Switching brands: within semaglutide, switching from one approved product to another is straightforward under medical guidance.
- Tirzepatide (Mounjaro): a different molecule entirely, available if appropriate for you, though pricier.
Out of stock and need a dose?
Message our care team. We can review your current dose and arrange a predictable, supervised supply of the same molecule.
How to never run dry again
The most reliable way to avoid stockout anxiety is to be on a supervised programme built around a domestic generic supply, with a doctor managing your dose and refills ahead of time rather than you chasing pens reactively. That's how ALTRcare's programme is structured: same molecule, predictable monthly supply, dose adjusted by a doctor, from ₹3,999 a month.
Switching safely
Moving between semaglutide products should be done at an equivalent dose under guidance, not guessed. If you're mid-titration, your doctor will match the dose so you don't lose progress or trigger side effects.
Key takeaways
- GLP-1 stockouts stall progress and can revive side effects on restart, continuity matters.
- Shortages stem from global demand and reliance on imported brand supply.
- Since March 2026, 40+ domestic generic semaglutide makers mean the molecule is no longer scarce.
- A supervised programme with predictable domestic supply is the reliable fix.
Want a supply you can rely on?
Take the 2-minute assessment to move to a supervised programme with predictable monthly delivery.
Frequently asked questions
What can I take if Ozempic is out of stock in India?
Generic semaglutide, the identical molecule, DCGI-approved and made domestically, with pens from ₹1,800/month, is the most direct substitute. Switching should be done at an equivalent dose under medical guidance.
Is it safe to switch from branded Ozempic to a generic?
Yes, because it's the same molecule. The key is matching your current dose and continuing supervision so you don't lose progress or trigger side effects.
When will Wegovy be reliably in stock in India?
Brand supply can still fluctuate with global demand. The more reliable route in 2026 is a supervised programme built on domestic generic semaglutide, where supply is spread across many manufacturers.
Sources
- India's GLP-1 market nears Rs 2,000 crore as semaglutide boom slows (Medical Dialogues, 21 June 2026)
- Anti-obesity market stabilises as semaglutide generics plateau (BioSpectrum India, 11 July 2026)
- Novo Nordisk India sets price of Rs 202/day for starting dose of Ozempic and Wegovy (Indian Pharma Post, 31 March 2026)
- India seizes suspected fake Mounjaro pens, says raw materials sourced from Alibaba (Reuters via GDN, 20 April 2026)
Ready to take the next step?
Take the free 2-minute eligibility assessment. A doctor reviews it before anything is prescribed, with no obligation.
This article is for general educational purposes and is not a substitute for personalised medical advice. GLP-1 medications are prescription-only and not suitable for everyone. Always consult a qualified doctor before starting, changing, or stopping any treatment.
